发明名称 COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS
摘要 The present invention relates to compounds of formula (I) in which R1, R2, R3 and R4 are as defined in the Summary of the Invention. Compounds of formula I are capable of disrupting the BCL-2 interations with proteins containing a BH3 domain. Disrupting this interaction can restore the anti-apoptotic function of BCL-2 in cancer cells and tumor tissue expressing BCL-2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancerous diseases.;
申请公布号 US2015080428(A1) 申请公布日期 2015.03.19
申请号 US201214366858 申请日期 2012.12.12
申请人 NOVARTIS AG 发明人 Visser Michael Scott;Yusuff Naeem
分类号 C07D401/10;C07D405/14;C07D413/14;C07D401/14;A61K31/4725;C07D409/14 主分类号 C07D401/10
代理机构 代理人
主权项 1. A compound of formula I: in which: R1 is selected from hydrogen and halo; R2 is selected from hydrogen and C1-4alkyl; wherein R2 is in the meta position and R3 is in the para position relative to the pyrazole ring or R2 is in the para position and R3 is in the meta position relative to the pyrazole ring; R3 is selected from hydroxy and -L-R5; wherein L is —NHS(O)2X1—; wherein X1 is selected from a bond and branched or unbranched C1-4alkylene; wherein said alkylene of X1 can be unsubstituted or substituted with a group selected from carboxy-methyl, methoxy-carbonyl-methyl, methyl-carbonyl-amino, hydroxy-methyl and phenyl; R4 is selected from hydrogen, hydroxy, —X3NR8R9, —X3C(O)OR8, —X3OR8, —X3C(O)NR8R9 and —X3NR8C(O)R9; wherein X3 is selected from a bond and C1-4alkylene; and R8 and R9 are independently selected from hydrogen, C1-4alkyl and phenyl; or R8 and R9 together with the nitrogen to which R8 and R9 are attached form a 5 to 7 member saturated ring containing 1 to 3 groups or heteroatoms independently selected from C(O), NR10, O and S(O)0-2; wherein R10 sis selected from hydrogen and C1-4alkyl; R5 is selected from hydrogen, C1-6alkyl, C2-6alkenyl, cyclopropyl, imidazo[1,2-a]pyrimidinyl, 2-oxo-4-phenylpiperazin-1-yl, 4-(2-chlorobenzyl)-3-oxopiperazin-1-yl, imidazo[1,2-a]pyridinyl, benzo[d]isoxazolyl, naphtho[2,1-d][1,2,3]oxadiazol-5-yl, 1H-pyrrolo[2,3-b]pyridinyl, imidazo[2,1-b]thiazolyl, 1H-pyrazolo[3,4-b]pyridinyl, benzo[c][1,2,5]thiadiazolyl, 4-oxo-4,5,6,7-tetrahydrobenzofuranyl, (7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methyl, benzo[c][1,2,5]oxadiazolyl, 2-oxo-1,2,3,6-tetrahydropyrimidinyl, 1,2,4-oxadiazolyl, 2,3-dihydrobenzo[b][1,4]dioxin-2-yl, naphtho[2,3-d][1,3]dioxol-2-yl, 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl, 2,3-dihydrobenzofuran-3-yl, chroman-8-yl, 3-oxo-3H-pyrazolyl, 6-oxo-1,6-dihydropyridazinyl, benzo[b]thiophenyl, dimethyl-amino, benzo[b]furanyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, isoindoline-1,3-dionyl, 2-oxo-1,2-dihydropyridinyl, 2-oxo-1,2,5,6,7,8-hexahydroquinolinyl, 4-oxo-1,4-dihydro-1,8-naphthyridinyl, 4-oxo-4H-pyrano[2,3-b]pyridinyl, 10,10-dioxido-9-oxo-9H-thioxanthen-3-yl, 5-oxopyrrolidin-3-yl, phenyl, quinolinyl, isoquinolinyl, benzyl, phenoxy, phenylthio, benzoxy, phenyl-sulfonyl, furanyl, thiazolyl, oxazolyl, isoxazolyl, thienyl, pyrrolyl, quinolin-8-yloxy, pyrimidinyl, pyridinyl, pyrrolidinyl, pyrrolidinonyl, imidazolidine-2,4-dionyl, piperidinyl, piperazinyl, pyrazinyl, pyrazolyl, morpholino, oxomorpholino, indolyl, benzo[b]thiophenyl, benzo[b]furanyl, benzo[d][1,2,3]triazol and oxopiperazinyl; wherein said C1-6alkyl, C2-6alkenyl, cyclopropyl, imidazo[1,2-a]pyrimidinyl, benzo[d]isoxazolyl, imidazo[1,2-a]pyridinyl, 4-oxo-4,5,6,7-tetrahydrobenzofuranyl, 2-oxo-1,2,3,6-tetrahydropyrimidinyl, imidazo[2,1-b]thiazolyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrazolo[3,4-b]pyridinyl, 1,2,4-oxadiazolyl, benzo[c][1,2,5]thiadiazolyl, 2,3-dihydrobenzo[b][1,4]dioxin-2-yl, naphtho[2,3-d][1,3]dioxol-2-yl, 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, benzo[c][1,2,5]oxadiazolyl, isoindoline-1,3-dionyl,2,3-dihydrobenzofuran-3-yl, chroman-8-yl, 3-oxo-3H-pyrazolyl, 6-oxo-1,6-dihydropyridazinyl, 2-oxo-1,2-dihydropyridinyl, 2-oxo-1,2,5,6,7,8-hexahydroquinolinyl, 4-oxo-1,4-dihydro-1,8-naphthyridinyl, 4-oxo-4H-pyrano[2,3-b]pyridinyl, 10,10-dioxido-9-oxo-9H-thioxanthen-3-yl, 5-oxopyrrolidin-3-yl, phenyl, quinolinyl, isoquinolinyl, phenoxy, benzyl, benzoxy, phenoxy-methyl, phenylthio, phenyl-sulfonyl, furanyl, thiazolyl, oxazolyl, isoxazolyl, thienyl, pyridinyl, pyrrolyl, quinolin-8-yloxy, pyrrolidinyl, pyrimidinyl, pyrrolidinonyl, piperazinyl, piperidinyl, pyrazinyl, pyrazolyl, morpholino, oxomorpholino, indolyl, benzo[d][1,2,3]triazol or oxopiperazinyl of R5 is unsubstituted or substituted with 1 to 3 groups independently selected from halo, cyano, nitro, —NR6R7, C1-4 alkyl, halo-substituted-C1-4 alkyl, C1-4 alkoxy, halo-substituted-C1-4 alkoxy, halo-substituted-C1-4alkylthio, —C(O)OR6, —X3OR6, —C(O)R6, —C(O)NR6R7, —NR6S(O)2X3R7, —X3NR6C(O)R7, —S(O)0-2R6, —S(O)0-2NR6R7, phenyl, benzyl, oxazolyl, naphthyl, piperidinyl, pyrrolidinyl, morpholino, morpholino-methyl, 1,2,4-oxadiazolyl, pyrazolyl, phenoxy, indolyl, (1H-1,2,4-triazolyl)methyl and benzoxy; wherein R6 and R7 are independently selected from hydrogen, C1-4alkyl, C3-8cycloalkyl, pyridinyl, phenyl, benzyl and naphthyl; wherein said phenyl, pyridinyl, benzyl, morpholino, morpholino-methyl, 1,3-dioxoisoindolinyl, 1,2,4-oxadiazolyl, pyrazolyl, indolyl and benzoxy substituents of R5 or said pyridinyl and phenyl of R6 or R7 can be unsubstituted or further substituted with a group selected from halo, nitro, amino-sulfonyl, C1-4alkyl, C1-4alkoxy and halo-substituted-C1-4alkyl; wherein X3 is selected from a bond and C1-4alkylene; or the pharmaceutically acceptable salt thereof; with the proviso that compounds of formula I do not include the compound where R1 is hydrogen, R2 is hydrogen and R3 is —NHSO2CH2-phenyl.
地址 Basel CH